Sanofi / Regeneron pipeline at a glance (March 2026)
About the Sanofi / Regeneron clinical program
Sanofi and Regeneron operate an extensive co-development partnership spanning immunology, oncology, and rare disease. Dupixent (dupilumab), the IL-4Rα-blocking antibody, is the fastest-growing biologic in history — and Sanofi continues expanding its label into new type-2 inflammatory conditions (COPD, prurigo nodularis, alopecia areata). Their shared oncology pipeline includes cemiplimab (Libtayo), the PD-1 inhibitor with approvals in skin cancers and NSCLC, plus a broad REGN antibody program in hematology and solid tumors. Sanofi's rare disease heritage (Gaucher, Pompe, Fabry) continues with next-generation enzyme replacement therapies and gene therapies.
Key therapeutic areas
- Type-2 inflammation / allergy (IL-4Rα, IL-33, TSLP)
- Oncology (PD-1, bispecifics, hematology)
- Rare / metabolic disease (lysosomal storage, hemophilia)
- Neurology
- Vaccines (Beyfortus RSV)
Key pipeline programs
- Dupixent (dupilumab) — IL-4Rα, atopic dermatitis/asthma/COPD
- Libtayo (cemiplimab) — PD-1, skin cancers/NSCLC
- Sarclisa (isatuximab) — anti-CD38, multiple myeloma
- Zynquista (sotagliflozin) — SGLT1/2, T1D/heart failure
- REGN5458 — BCMAxCD3 bispecific, myeloma
- Fitusiran — RNAi-based hemophilia therapy
Monitor the Sanofi / Regeneron pipeline daily
Get alerts when Sanofi / Regeneron registers new trials or updates existing protocols. Free 14-day trial — no credit card required.
Start Monitoring FreeTop Sanofi / Regeneron trial indications
| Condition / Indication | Trials |
|---|---|
| ["Asthma"] | 7 |
| ["Dermatitis Atopic"] | 7 |
| ["Chronic Rhinosinusitis With Nasal Polyps"] | 6 |
| ["Atopic Dermatitis"] | 5 |
| ["Type 1 Diabetes"] | 4 |
| ["Chronic Obstructive Pulmonary Disease"] | 4 |
| ["Crohn's Disease"] | 4 |
| ["Paroxysmal Nocturnal Hemoglobinuria"] | 3 |
Why monitor Sanofi / Regeneron's clinical trial activity
Dupixent's label expansion program generates consistent new trial registrations across type-2 inflammatory conditions. Any company developing IL-4, IL-13, IL-33, or TSLP-targeted therapies needs to monitor Sanofi/Regeneron's trial activity closely.
DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Sanofi / Regeneron's registered studies — new trial registrations, status transitions (e.g., "Not yet recruiting" → "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and real-time pipeline developments.
How DataLookout tracks Sanofi / Regeneron trials
- Sponsor normalization: Sanofi / Regeneron may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
- Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
- Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced — not just new registrations.
- Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
- Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.
Automate your Sanofi / Regeneron pipeline intelligence
Used by pharma BD, strategy, and competitive intelligence professionals. Setup takes under 5 minutes.
Start Free TrialFrequently asked questions
What indications are Sanofi/Regeneron currently trialing Dupixent in?
Beyond approved indications (atopic dermatitis, asthma, CRSwNP, EoE, prurigo nodularis, alopecia areata, COPD), Sanofi/Regeneron has active Dupixent trials in additional type-2 inflammatory conditions. DataLookout surfaces new registrations as they appear on ClinicalTrials.gov.
How many Sanofi/Regeneron trials are currently recruiting?
Based on current ClinicalTrials.gov data, 121 Sanofi and Regeneron-sponsored trials are actively recruiting. This normalizes across both companies' trial registrations.
Does DataLookout track both Sanofi and Regeneron separately?
DataLookout normalizes Sanofi and Regeneron trials into a single canonical entity for the shared pipeline, while also allowing you to filter by individual entity if needed. Their co-sponsored trials (particularly Dupixent and Libtayo) appear under either company's name on ClinicalTrials.gov.